AstraZeneca: Lymphoma, Mantle-Cell trials
The registry lists 15 Lymphoma, Mantle-Cell studies with AstraZeneca as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 1 7Phase 2 8Phase 3 2Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainRecruitingNCT07029737Phase 2
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/2
- Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
- Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
- Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaActive, not recruitingNCT02213926Phase 2Results posted
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
- A Disease Registry of Patients With Mantle Cell LymphomaCompletedNCT03816683
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLActive, not recruitingNCT02717624Phase 1
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1